Robyn Hunter - Fortress Biotech Ex Officer

All Insiders USA . 
Preferred Stock . Fortress Biotech Pref . Stakeholders . Insider . Robyn Hunter
FBIOP Preferred Stock  USD 6.98  0.18  2.65%   

Executive

Ms. Robyn Hunter serves as Chief Financial Officer of the company. Ms. Hunter has more than 30 years of financial and operational experience in an array of industries. Since June 2011, Ms. Hunter has served as the Companys Vice President and Corporationrationrate Controller where she has implemented financial and operational processes, procedures and policies to facilitate the Companys execution of its growth strategy. From January 2006 to May 2011, Ms. Hunter served as Senior Vice President and Chief Financial Officer of Schochet Associates. From August 2004 to January 2006, Ms. Hunter served as the Corporationrationrate Controller for Indevus Pharmaceuticals. From 1990 to 2004, Ms. Hunter held several positions from Accounting Manager to Vice President and Treasurer of The Stackpole Corporation since 2017.
Age 61
Tenure 8 years
Phone781 652 4500
Webhttps://www.fortressbiotech.com
Hunter holds a Bachelor of Arts degree in Economics from Union College in Schenectady New York.

Fortress Biotech Management Efficiency

The company has return on total asset (ROA) of (0.3494) % which means that it has lost $0.3494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4338) %, meaning that it generated substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Fortress Biotech Pref has accumulated 46.56 M in total debt with debt to equity ratio (D/E) of 0.81, which is about average as compared to similar companies. Fortress Biotech Pref has a current ratio of 2.79, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Fortress Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Fortress Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Fortress Biotech Pref sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Fortress to invest in growth at high rates of return. When we think about Fortress Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Tariq AhmedAchilles Therapeutics PLC
N/A
James TaylorAchilles Therapeutics PLC
63
Rafael MDAptose Biosciences
53
Erin OBoyleRezolute
N/A
James MurphyMustang Bio
67
Gopal MBBSRezolute
N/A
Roger BScAptose Biosciences
N/A
Philippe LedruAptose Biosciences
56
Debra SPHRMustang Bio
N/A
Lee SternAchilles Therapeutics PLC
N/A
Richard MSMustang Bio
N/A
MS MBARezolute
51
Stephen RaillardKodiak Sciences
N/A
MD MPHKodiak Sciences
N/A
Marc WilesAptose Biosciences
N/A
Almas MScKodiak Sciences
N/A
Pablo MDKodiak Sciences
N/A
Samuel BerryFortress Biotech
N/A
Michael LouieKodiak Sciences
N/A
Daniel HoodAchilles Therapeutics PLC
N/A
Samuel MDTempest Therapeutics
59
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York. Fortress Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 173 people. Fortress Biotech Pref (FBIOP) is traded on NASDAQ Exchange in USA. It is located in 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 and employs 173 people. Fortress Biotech is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Return On Equity-1.43
Return On Asset-0.35

Fortress Biotech Pref Leadership Team

Elected by the shareholders, the Fortress Biotech's board of directors comprises two types of representatives: Fortress Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fortress. The board's role is to monitor Fortress Biotech's management team and ensure that shareholders' interests are well served. Fortress Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fortress Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lindsay Rosenwald, Chairman of the Board and Presidentident, CEO
Samuel Berry, Gen Sec
Robyn Hunter, Ex Officer
Michael Esq, Vice Devel
Thomas Schaible, Project Disease
George Avgerinos, Senior Vice President - Biologics Operations
David Jin, CFO Devel

Fortress Preferred Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right preferred stock is not an easy task. Is Fortress Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Number Of Shares Shorted245

Additional Tools for Fortress Preferred Stock Analysis

When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY